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Cyclin-dependent kinase inhibitors (CKIs) and Notch receptor activation have been shown 
to influence adult stem cells and progenitors by altering stem cell self-renewal and 
proliferation. Yet, no interaction between these molecular pathways has been defined. Here 
we show that ligand-independent and ligand-dependent activation of Notch1 induces 
transcription of the S phase kinase–associated protein 2 (SKP2), the F-box subunit of 
the ubiquitin-ligase complex SCF
 
SKP2
 
 that targets proteins for degradation. Up-regulation 
of SKP2 by Notch signaling enhances proteasome-mediated degradation of the CKIs, 
p27
 
Kip1
 
 and p21
 
Cip1
 
, and causes premature entry into S phase. Silencing of SKP2 by RNA 
interference in G
 
1
 
 stabilizes p27
 
Kip1
 
 and p21
 
Cip1
 
 and abolishes Notch effect on G
 
1
 
-S 
progression. Thus, SKP2 serves to link Notch1 activation with the cell cycle machinery. This 
novel pathway involving Notch/SKP2/CKIs connects a cell surface receptor with proximate 
mediators of cell cycle activity, and suggests a mechanism by which a known physiologic 
mediator of cell fate determination interfaces with cell cycle control.
 
Members of the Notch/Lin12 family are
highly conserved transmembrane receptors
that influence the cell fate of diverse types of
precursor cells in a variety of multicellular or-
ganisms (1). Physiologic activation of Notch
signaling requires cell–cell contact and occurs
through binding of the Notch receptor to one
of its ligands (Delta, Serrate/Jagged), followed
by proteolytic release of the Notch intracellu-
lar domain (Notch
 
ic
 
) and its translocation to
the nucleus (2). Notch
 
ic
 
 interacts with CSL
transcription factors (CBF1, Su(H), Lag-1)
and converts them from repressors to activa-
tors, promoting transcription of downstream
genes involved in various differentiation pro-
grams (3).
In many cellular systems, Notch activation
affects the finely tuned balance between prolif-
eration and differentiation that regulates the
stem and progenitor cell pools (1, 4, 5). Regu-
lation of cell differentiation and cell fate deci-
sion by Notch is achieved by induction of
specific differentiation programs and by an inde-
pendent regulation of the cell cycle. Notch acti-
vation has been shown to induce alterations of
the cell cycle kinetics that precede the inhibi-
tion of myeloid differentiation in hematopoietic
cells (6), and to influence keratinocyte differ-
entiation by two distinct mechanisms that in-
volve induction of cell cycle arrest through
p21
 
Cip1
 
 and transcriptional regulation of spe-
cific genes (4).
Regulation of the cell cycle by Notch sig-
naling involves the coordination of different,
and sometimes antagonizing, pathways in a
highly cell context–dependent manner. For
example, Notch activation has been found to
induce proliferation of kidney epithelial cells
through induction of cyclin D
 
1
 
 (7), and to lead
to cell cycle arrest in keratinocytes through
induction of p21
 
Cip1
 
 (4). These observations
indicate the existence of multiple alternative
molecular interactions between Notch signal-
ing and the cell cycle machinery, which are
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likely to correlate with the ability of Notch to function as an
oncogene or a tumor suppressor (8, 9).
Physiologic regulation of the G
 
1
 
-S transition is critical
during determination of cell fate and is lost during oncogenic
transformation. Cyclin-dependent kinases (CDKs) and cy-
clin-dependent kinase inhibitors (CKIs) play key roles in
regulating cell cycle progression from G
 
1
 
 to S phase (10).
Absence of the CKIs, p21
 
Cip1
 
 or p27
 
Kip1
 
, affect self-renewal
of hematopoietic stem cells (11) and the proliferation/differ-
entiation balance of hematopoietic progenitors (12), respec-
tively, and predispose cells to neoplastic transformation (13).
In this study, we explore the role of Notch signaling at
the defined G
 
1
 
–S phase transition of the cell cycle. We
found that Notch1 (N1) activation reduces the permanence
of the cells in G
 
1
 
 and accelerates their entry into S phase by
promoting transcriptional induction of the F-box protein,
SKP2, and in turn, proteasome-mediated degradation of the
CKIs, p21
 
Cip1
 
 and p27
 
Kip1
 
 (14, 15). Thus, enhancement of
SKP2 transcription represents a mechanism by which Notch
modulates timing of cell cycle progression and coordinates
proliferation and differentiation decisions.
 
RESULTS
Notch1 activation induces premature cell cycle entry and its 
effect is enhanced by the lack of p21
 
Cip1
 
We demonstrated previously that N1 activation induces a
more rapid G
 
1
 
-S transition in hematopoietic progenitors (6).
To identify the mechanisms that mediate this effect, we de-
termined whether the alterations in cell cycle kinetics caused
by N1 activation were enhanced in the absence of the G
 
1
 
regulatory molecule, p21
 
Cip1
 
, which was shown to mediate
Notch-induced cell cycle arrest in some cell types (4). WT
and p21
 
Cip1
 
 knock-out (p21
 
 
 
/
 
 
 
) 3T3 fibroblasts transduced
with the retroviral bicistronic construct MSCV-GFP con-
taining the constitutively activated forms of N1, (ICN) in-
tracellular domain of Notch, and 
 
 
 
E (intracellular with
transmembrane domain of Notch) (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20050559/DC1)
were synchronized by nocodazole block-and-release and
screened for alterations in the G
 
1
 
 to S phase transition. This
analysis (Fig. 1, A and B) showed that constitutively active
N1 increases the percentage of cells in S phase in WT cells
(
 
 
 
10–15%) and that the magnitude of this effect is signifi-
cantly greater in the absence of p21
 
Cip1
 
 (
 
 
 
20–30%). Despite
the effects of N1 on cell cycle kinetics, Notch activation did
not affect the overall cell cycle length and cell proliferation
(Fig. 1 C). Preservation of total cell cycle length has been
also observed in other 3T3 cells in which the G
 
1
 
 phase of the
cell cycle was shortened (16). Furthermore, overexpression
of constitutively active N1 did not induce transformation in
WT or p21
 
 
 
/
 
 
 
 fibroblasts, as measured by soft agar colony
assays (unpublished data).
These results show that the expression of constitutively
active N1 in 3T3 fibroblasts accelerates G
 
1
 
 transition without
increasing rates of proliferation, and that this effect is en-
hanced by the lack of the CKI, p21
 
Cip1
 
. Furthermore, these
observations suggest that additional cell cycle regulators me-
diate Notch effects on the cell cycle and that p21
 
Cip1
 
 may
play a role in balancing such effects.
 
Notch1 activation induces p27
 
Kip1
 
 down-regulation and 
enhances CDK2 kinase activity
 
Next, we determined whether N1 activation altered the activ-
ity of CDK2 or CDK4 complexes, both critical for S phase
entry and progression. WT and p21
 
 
 
/
 
 
 
 3T3 cells transduced
with constitutively active N1 exhibited a significant increase
in CDK2 kinase activity compared with control cells, whereas
no significant differences were observed in CDK4 activity
(Fig. 2 A). The greater kinase activity was not due to increased
cyclin levels because all cell lines expressed similar levels of cy-
clin D
 
1
 
, A, and E, as well as CDK2 and CDK4 (Fig. 2 B).
Because CDK2 activity is antagonized strongly by the
CKIs of the Cip/Kip family, p21
 
Cip1
 
 and p27
 
Kip1
 
, we tested
Figure 1. Biologic effects of N1 activation on 3T3 WT and p21 /  
fibroblasts. (A) Percentage of cells in S phase during cell cycle progression. 
The cell cycle entry of transduced 3T3 cells was evaluated by bromodeoxyuri-
dine incorporation. Values represent an average of duplicate samples in a 
representative experiment. (B) Bars indicate the average percentage of 
cells in S phase at 6 h after nocodazole block and release in five indepen-
dent experiments. The difference between GFP and  E populations is sta-
tistically significant. (C) Cell division kinetics. Cells stained with PKH26-GL 
were seeded at low density and analyzed by FACS. The line graphs show a 
representative experiment. Values indicate PKH 26-GL mean intensity of 
fluorescence (MIF), decaying over time during cells’ exponential growth. 
JEM VOL. 202, July 4, 2005
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the possibility that the greater CDK2 kinase activity ob-
served in the presence of N1 in WT and p21
 
 
 
/
 
 
 
 cells was
due to a lower level of CDK2 inhibition by decreased levels
of p27
 
Kip1
 
. We found that p27
 
Kip1
 
 expression was signifi-
cantly lower in WT and p21
 
 
 
/
 
 
 
 cells transduced with con-
stitutively active N1 (Fig. 2 C and Fig. 3 A). In the WT
background, p27
 
Kip1
 
 levels in 
 
 
 
E and ICN cells were 80 and
60% of control GFP cells, respectively; in the p21
 
 
 
/
 
 
 
 back-
ground, p27
 
Kip1
 
 levels in 
 
 
 
E and ICN cells were 50 and 30%
of control GFP cells, respectively (Fig. 2 D).
To confirm that p27
 
Kip1
 
 down-regulation was a direct
consequence of Notch activity, 3T3 cells expressing consti-
tutively active N1 were treated with a 
 
 
 
-secretase inhibitor
(GSI). GSIs have been shown to impair activation of full-
length Notch and Notch/
 
 
 
E by blocking the proteolytic in-
tracytoplasmic cleavage that occurs in membrane-tethered
forms of Notch (17). Inhibition of this process blocks the
generation of the active cleaved form of Notch, Notch
 
ic
 
, and
results in the accumulation of an intermediate inactive form
of Notch, the metalloprotease cleavage product (
 
 
 
E*; refer-
ence 18). Treatment of p21
 
 
 
/
 
 
 
 
 
E cells with GSI caused the
inhibition of Notch cleavage and could be observed as an ac-
cumulation of 
 
 
 
E* polypeptide. Block of Notch signaling
by GSI resulted in the abolishment of Notch-induced
p27
 
Kip1
 
 down-regulation (Fig. 2 E). Thus, activation of N1
induces a specific down-regulation of p27
 
Kip1
 
 in asynchro-
nous WT and p21
 
 
 
/
 
 
 
 cells.
 
Notch1 activation promotes p27
 
Kip1
 
ubiquitin-mediated degradation
 
To explore the molecular bases for N1-induced p27
 
Kip1
 
down-regulation, we tested whether this effect was depen-
dent on the proteasome-degradation pathway, which is the
prevalent mechanism of p27
 
Kip1
 
 regulation in many cellular
systems (19). Treatment with the 26S proteasome-specific
inhibitor, lactacystin, reestablished high levels of p27
 
Kip1
 
 in
WT and p21
 
   
 
 cells overexpressing constitutively active N1
(
 
 
 
E and ICN; Fig. 3 A); this confirmed the involvement of
this pathway in Notch-mediated p27
 
Kip1
 
 down-regulation.
We further investigated p27
 
Kip1
 
 half-life by treating ICN-
expressing cells and controls with 10 
 
 
 
M of the ribosomal
complex inhibitor, cycloheximide. As shown in Fig. 3 B,
p27
 
Kip1
 
 disappears more rapidly in ICN cells than in controls,
showing a shorter half-life of p27
 
Kip1
 
 in the presence of acti-
vated N1 (
 
 
 
2 h in ICN cells versus 4 h in controls). Finally,
to determine if N1 activation enhances p27
 
Kip1
 
 ubiquitina-
tion, we evaluated p27
 
Kip1
 
 ubiquitinated forms in vivo. En-
dogenous p27
 
Kip1
 
 was immunoprecipitated from extracts of
 
 
 
E and control cells that had been treated with the protea-
some inhibitor, MG132, which is used to stabilize ubiquitin-
ated intermediates. MG132 treatment had the same ef-
fects as did lactacystin treatment on GFP and 
 
 
 
E cells (Fig.
S2, available at http://www.jem.org/cgi/content/full/
jem.20050559/DC1). Immunoprecipitates were subjected
to immunoblot analysis with anti-p27
 
Kip1
 
 antibodies to de-
Figure 2. N1 activation correlates with increased CDK2 kinase 
activity and promotes p27Kip1 down-regulation. (A) In vitro kinase 
activity assay (K.A.) of immunoprecipitated CDK2 (K2) or CDK4 (K4) com-
plexes from growing cells. Histone (H1) or retinoblastoma (Rb) was used as 
substrate, respectively. (B) Immunoblot of cyclins and CDKs. (C) Immuno-
blot of p27Kip1. p21 /  cells express higher levels of p27Kip1 compared with 
WT, perhaps as a compensatory mechanism. In this blot, where WT and 
p21 /  cells are side by side, p27Kip1 in WT samples is underexposed to 
avoid its overexposure in p21 /  samples. (D) ImageQuant densitometric 
analysis of p27Kip1 protein expression. The values, an average of five inde-
pendent experiments, indicate percentage of p27Kip1 protein detected in 
 E or ICN cells relative to their GFP controls (100%). (E) Cells were incu-
bated with the GSI ( ) or DMSO vehicle control ( ) for 12 h. Protein 
extracts from harvested cells were analyzed by Western blot to assess N1 
and p27Kip1 expression.SKP2 IS A TARGET OF NOTCH SIGNALING | Sarmento et al. 160
tect the different migrating forms of p27Kip1 (Fig. 3 C). Un-
der these conditions, p27Kip1 showed a basal level of ubiqui-
tination that was increased significantly in the presence of N1
activation. Only p27Kip1 immunoprecipitates from cells over-
expressing   E treated with MG132 contained detectable
levels of slow migrating polyubiquitinated derivatives (inset,
Fig. 3 C, lanes 3 and 6). Presence of more highly ubiquitin-
ated forms could not be detected due to interference with
the assay by IgG heavy chain. Together, these findings show
that N1 activation results in a rapid decrease of p27Kip1 levels
by enhancing proteasome-mediated degradation of the
p27Kip1 protein.
Notch1 regulates SKP2 and p27Kip1 levels in 
a cell cycle–dependent manner
Because p27Kip1 degradation is regulated by the SKP1/
CUL1/F-box (SCF)SKP2-ubiquitination complex during
cell cycle progression (14), we tested the hypothesis that
Notch activation decreased p27Kip1 levels by regulating
molecules that are involved in its degradation (e.g., the
F-box protein, SKP2). We determined whether N1 activa-
tion altered the kinetics of SKP2 expression during cell cy-
cle progression. In cells synchronized by nocodazole block-
release or by serum starvation-stimulation, entry into the
cell cycle was characterized by the induction of SKP2 pro-
Figure 3. N1 activation induces ubiquitin-proteasome–mediated 
degradation of p27Kip1. (A) Proteasome inhibition. Transduced 3T3 cells 
were incubated with DMSO (vehicle control) or the proteasome inhibitor, 
lactacystin. Cell extracts were analyzed by Western blot for p27Kip1 expression. 
(B) p27Kip1 protein half-life. Transduced 3T3 cells were arrested by nocoda-
zole block. Cycloheximide was added 6 h after release into cell cycle and 
samples were incubated with cycloheximide for the indicated time points 
before lysis. p27Kip1 protein levels were determined by Western blot (top 
panel) and their densitometric values normalized to  -actin, densitometric 
units (DU) were plotted as line graphs (bottom panel). (C) In vivo detection 
of ubiquitin conjugates. Cell extracts from p21 /  GFP and  E cells 
treated with MG132 or DMSO, were immunoprecipitated with anti-p27Kip1 
antibodies or with IgG controls, separated by SDS-PAGE and blotted with 
anti-p27Kip1 antibodies. The inset shows a darker exposure of the blot for 
detection of slowly migrating forms of p27Kip1.JEM VOL. 202, July 4, 2005 161
ARTICLE
tein in both GFP and  E cells. However, such induction
was more rapid and greater in the presence of activated N1
than in control cells (Fig. 4, A and D). SKP2 levels were
consistently two- to threefold higher in  E cells than in
controls (Figs. 4 B and 5 B), and were especially higher at
the early time points of cell cycle entry. The more rapid in-
crease of SKP2 protein in  E cells was paralleled remark-
ably by a more rapid and significant degradation of p27Kip1
in these cells (Fig. 4, A, C, and D; and Fig. 5 B). At 6 h
from nocodazole block release, p27Kip1 expression in  E
cells decreased an average of 70% from the initial level,
whereas it decreased only an average of 40% in control cells
(Fig. 4 C). Recently, p21Cip1 was reported to be a target of
the SCFSKP2 complex (15). Similar to p27Kip1, p21Cip1 was
down-regulated faster in  E-expressing cells than in con-
trol cells (Fig. 4 D; Fig. 5, A and B).
To demonstrate further the role of SKP2 in N1-medi-
ated p27Kip1 degradation, GFP and  E cells were transfected
with small interfering RNA (siRNA) against SKP2 during
serum-induced cell cycle entry. Transfection of the siRNA
against SKP2, but not a control siRNA, decreased the level
of SKP2 to the limit of detection and prevented N1-induced
p27Kip1 and p21Cip1 degradation (Fig. 5, A and B). Accumu-
lation of p27Kip1, consequent to SKP2 depletion, was equiva-
lent in GFP and  E cells and resulted in an overall delay of
cell cycle entry, as reported by previous studies (20, 21).
Evaluation of S phase by Bromodeoxyuridine incorporation
indicated that in the presence of equivalent levels of p27Kip1,
the effect of activated N1 on cell cycle entry was reduced
dramatically (Fig. 5 C). In conclusion, these experiments
show that N1 activation has a direct impact on the kinetics
of SKP2 expression during cell cycle progression, and that
this effect correlates with decreased levels of the CKIs,
p27Kip1 and p21Cip1. Furthermore, we demonstrated that
SKP2 induction by N1 is required for Notch-induced
down-regulation of p27Kip1 (and p21Cip1) and consequent
modulation of cell cycle progression.
Notch1 activation induces CBF-1–dependent transcription 
of SKP2
Because the SKP2 promoter is targeted for regulation during
cell cycle progression and Notch promotes transcription of
several target genes through activation of the CBF-1/RBP-
J  transcription factor (4, 7), we hypothesized that Notch
signaling may regulate SKP2 at a transcriptional level. We
performed Northern blot quantification of SKP2 mRNA
during cell cycle progression, and we found that SKP2 tran-
scripts appear earlier and are more abundant in cells express-
ing activated N1 than in controls (Fig. 6, A and B). 
To define better the mechanism of induction of SKP2
mRNA by Notch, we searched for possible regulatory ele-
ments in the human SKP2 promoter region. We identified
and cloned a 3.1-kb region within the SKP2 promoter con-
taining the sequence TGGGAA at position –350 that fully
matches the consensus sequence of the high-affinity binding
site for CBF-1/RBP-J  (22), schematically represented in
Fig. 6 C. This consensus sequence is identical to the one
present in the murine HES-1 and p21Cip1 promoters (Fig. 6
C), which is transactivated by the Notchic/CBF-1 complex
(23). Electrophoretic mobility shift assay  (EMSA) analysis
showed that the protein-DNA complex could be identified
only when the radiolabeled SKP2 WT oligonucleotide was
incubated with extracts from 293T cells overexpressing CBF-1
(Fig. 6 D, lanes 2, 3, and 10); this confirmed the ability of
CBF-1 to bind to the identified SKP2 sequence. The CBF-
1–DNA complex was supershifted specifically by the anti–
CBF-1 (lane 6 and 7) and by the anti-N1 (lane 9) antibodies,
but not by an unrelated antibody (lane 10); its formation was
abolished by excess of unlabeled WT but not mutated SKP2
oligonucleotide (lanes 4, 8 and 5). In the nucleus, N1 physi-
cally associates with CBF-1, promoting transcriptional activ-
Figure 4. N1 activation enhances SKP2 expression and p27Kip1 
degradation during cell cycle progression. (A) Immunoblot of SKP2 and 
p27Kip1 during cell cycle progression induced by nocodazole block and 
release. (B) SKP2 expression at 6 h from nocodazole block and release was 
quantified by densitometric analysis and normalized with  -actin expression 
in Western blots of three independent experiments. Bars express average 
fold increase of SKP2 expression in  E cells compared with GFP. (C) Bars 
represent average percentage of p27Kip1 expression at 6 h relative to 2 h 
(100%) in four independent experiments. (D) Immunoblot of SKP2, p21Cip1, 
and p27Kip1 during serum-induced cell cycle progression.SKP2 IS A TARGET OF NOTCH SIGNALING | Sarmento et al. 162
ity (23). To determine whether the Notch/CBF-1 complex
binds to the endogenous SKP2 promoter, we performed
chromatin immunoprecipitation assay with anti–CBF-1 or
anti-N1 antibodies, followed by PCR amplification of the
SKP2 promoter region. Only DNA coprecipitated with anti–
CBF-1 or anti-N1 antibodies generated positive PCR prod-
ucts for the SKP2 promoter region containing the fully
conserved CBF-1 binding site (Fig. 6 E). PCR of the Hes1
promoter region containing the CBF-1 site and of the
CD11b promoter not containing the CBF-1 site, were per-
formed as positive and negative controls, respectively.
To determine whether activated Notch induces CBF-1-
dependent SKP2 transcription, we performed luciferase re-
porter assays on 3T3 fibroblasts following  E or ICN trans-
duction. Constitutive activation of N1 correlated with
significant transactivation of HES-1 and SKP2 promoters
(Fig. 6 F). SKP2 promoter activity increased  4- to 10-fold
in cells overexpressing activated N1 ( E and ICN) com-
pared with controls and paralleled HES-1 promoter activity,
which was used as a positive control for CBF-1–dependent
activity. Deletion of the CBF-1 binding motif resulted in the
abrogation of transcriptional activation (Fig. 6 G). In conclu-
sion, these data demonstrate that N1 activation promotes
CBF-1–dependent transcription of SKP2.
SKP2 expression is induced in vivo by physiologic activation 
of endogenous Notch1 by its ligand
To confirm the physiologic relevance of our findings, we
determined whether SKP2 expression could be induced by
ligand-dependent stimulation of endogenous Notch in he-
matopoietic cells. These cells express Notch receptors and,
in the BM microenvironment, are surrounded by neighbor-
ing cells expressing the Notch ligands Jagged1 (J1), Jagged2
(J2), Delta-like (Dll)1, and Dll4 (reference 24). We demon-
strated previously that J2-dependent stimulation of the he-
matopoietic cells HL-60 results in accelerated G1-S transition
and in delayed myeloid differentiation in the presence of all-
trans-retinoic acid (ATRA; reference 6). We generated mu-
rine stromal MS5 cell lines (25) overexpressing each of the
Notch ligands (J1, J2, Dll1, and Dll4) and screened their ef-
fect on HL-60 cells. This analysis indicated that Dll4 induces
the strongest inhibitory effect on HL60 cell differentiation,
which is recapitulated by a recombinant Dll4-Fc fusion pro-
tein (unpublished data). Next, we determined whether Dll4-
dependent stimulation of endogenous N1 induced SKP2 ex-
pression and p27Kip1 down-regulation in HL-60 cells (Fig. 7
A). Incubation with Dll4 ligand induced strong activation of
Notch signaling, confirmed by the induction of the cleaved
active form of N1, Notchic (Fig. 7 B). N1 activation upon
Figure 5. SKP2 is required for Notch effect on p27Kip1. (A) WT-GFP 
and WT- E were transfected with siRNA against SKP2 or GFP (negative 
control) during the serum starvation-stimulation procedure. Cell extracts 
were obtained at each indicated time point and analyzed by Western blot. 
The white lines indicate that intervening lanes have been spliced out. 
(B) Histogram summarizes multiple experiments at 12 h after serum stim-
ulation. SKP2, p27Kip1, and p21Cip1 protein levels were quantified from 
Western blot bands and normalized with  -actin values. Bars represent 
average densitometric units of four independent observations for GFP and 
 E cells, and two independent observations for  E cells in the presence of 
siSKP2. (*) Statistically significant differences between  E and GFP cells: 
SKP2 P   0.015; p27Kip1 P  0.033; p21Cip1 P   0.003. (C) Cells stimulated 
with serum in the absence or presence of SKP2 siRNA were pulsed with 
bromodeoxyuridine at 8 h and 12 h after stimulation. The difference be-
tween percentages of cells in S phase in  E and GFP cells were calculated. 
Bars represent averages of the differences expressed as percentage of S 
phase increment.JEM VOL. 202, July 4, 2005 163
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Figure 6. N1 activation induces CBF-1–dependent SKP2 transcrip-
tion. (A) Kinetics of SKP2 mRNA induction in 3T3 cells synchronized by 
nocodazole block-release by Northern blot (left panel); the line graph 
represents percentages of SKP2 expression normalized to  -actin over 
time (right panel). (B) Transduced 3T3 cells were synchronized by serum 
starvation and stimulation and were analyzed by Northern blot; values 
represent percentages of SKP2 expression normalized to  -actin. (C) Iden-
tification of CBF-1 binding site in the SKP2 promoter. Top panel: represen-
tation of the human SKP2 promoter region containing CBF-1. Bottom 
panel: comparison of known CBF-1 binding sites in different gene pro-
moters. (D) EMSA analysis was performed by incubating radiolabeled oli-
gonucleotide with no extract ( ) or lysates from 293T transfected with 
GFP or CBF-1. Radiolabeled WT oligonucleotide was incubated with lysates 
preincubated with 50-fold excess of unlabeled WT (wt) or mutated (mut) 
oligonucleotide for competition experiments (c.c.), and with unrelated 
antibody ( nr), anti-N1, or anti–CBF-1 antibodies for supershifts experi-
ments.   and    indicate that 2.5 and 5  l of ab were used. Specific 
CBF1-DNA complex is indicated as CBF1. (*) indicates the supershifted 
band obtained when anti–CBF-1 or anti-N1 antibodies were present in the 
binding mixture. (E) Binding of N1 and CBF1 to the endogenous SKP2 pro-
moter by chromatin IP analysis. SUPT1 cells, which express high levels of 
activated N1, were processed for chromatin immunoprecipitation with 
antibodies against CBF-1, N1, or affinity purified IgGs. Input DNA and 
recovered DNA were analyzed by PCR using specific primers for the indi-
cated promoters. In the Hes1 PCR, the input DNA lane is substituted by a 
nonimmune IP sample. Positive PCR products were generated from the in-
put DNA. (F) Increased SKP2 and HES-1 promoter activity in the presence 
of activated N1. Transduced 3T3 cells were transfected with the luciferase 
reporter plasmid containing the 3.1-kb SKP2 promoter (SKP2-luc) or the 
HES-1 promoter (HES-luc). Cells were harvested after 40 h and cell extracts 
were prepared for the luciferase reporter assays. All promoter activity 
studies are representative of at least three independent experiments. 
(G) Deletion of CBF-1 binding motif abrogates CBF-1/N1–dependent tran-
scription. Transduced 3T3 cells were transfected with the luciferase reporter 
plasmid containing the 3.1-kb SKP2 promoter (SKP2-luc) or the site specific 
deletion in the HES promoter ( -CBF1) that abrogate CBF-1/N1–dependent 
transcription. Cells were harvested after 40 h and cell extracts were pre-
pared for the luciferase reporter assays. Values represent the average per-
centage of luciferase relative units obtained using the  -CBF1 construct 
relative to SKP2 construct (100%).SKP2 IS A TARGET OF NOTCH SIGNALING | Sarmento et al. 164
Dll4 stimulation was accompanied by higher levels of SKP2
and failure to accumulate p27Kip1 (Fig. 7 B, lanes 3 and 4),
whereas in the control, response to ATRA treatment was
characterized by SKP2 down-regulation and p27Kip1 accu-
mulation (Fig. 7 B, lanes 1 and 2), as documented (26).
SKP2 transcripts increased after physiologic stimulation of
endogenous N1 by, Dll4 (Fig. 7 C). Dll4 stimulation of
Notch signaling was associated with resistance of HL-60 cells
to arrest in G1 and to differentiate (Fig. 7 D)—as we previ-
ously reported—with J2 stimulation (6). To prove that SKP2
up-regulation was directly due to Notch activation upon
Dll4 stimulation, we treated stimulated HL-60 cells with the
Notch inhibitor, GSI. GSI treatment induced a complete in-
hibition of N1 cleavage, prevented Dll4-mediated induction
of SKP2 and which resulted in p27Kip1 accumulation (Fig. 7
B, lanes 5 and 6), and promoted cell differentiation (Fig. 7
D). Similarly, expression of a dominant negative form of
SKP2 (SKP2 F) that prevents p27Kip1 degradation (14),
increased rates of differentiation in HL-60 cells (Fig. S3,
available at http://www.jem.org/cgi/content/full/jem.
20050559/DC1) which indicated a direct impact of SKP2
on cell differentiation. These experiments demonstrate that
ligand-dependent stimulation of endogenous N1 leads to
SKP2 induction and p27Kip1 down-regulation, and affects
cell differentiation.
Next, we examined whether the loss of N1 had an im-
pact on SKP2 expression and differentiation in vivo. To ad-
dress this question we used mice transgenic for an N1 anti-
sense (N1AS / ) driven by the mouse mammary tumor
virus LTR promoter, which specifically suppresses N1 tran-
scripts in a variety of cell types, including hematopoietic pre-
cursors (27, 28). Reduced N1 expression in N1AS /  corre-
lated with a modest, but reproducible, decrease in SKP2
transcripts (Fig. 8 A) and protein levels (not depicted), when
compared with controls (N1AS  and N1AS / ). Analysis of
the hematopoietic subsets in N1AS /  and control mice did
not show significant differences in the representation of
primitive Lin Sca  and myeloid mature Gr /Mac  subsets
in the BM and in the spleen (Fig. S4, available at http://
www.jem.org/cgi/content/full/jem.20050559/DC1), which
is consistent with recent observations made in an inducible
knock-out model (29). These data suggest that although
N1 activation may have a significant effect on SKP2 induc-
tion in adult hematopoietic cells, its absence likely is com-
pensated by other Notch receptors. Evaluation of the
Notch/SKP2 pathway should provide more useful infor-
mation in a model where Notch receptors signaling are ab-
rogated completely.
Finally, we evaluated the effects of Notch stimulation and
inhibition in primary hematopoietic cells. BM Lin  cells (en-
riched in progenitors) were sorted from control mice and
were stimulated with Dll4 in the absence or presence of GSI.
Dll4 stimulation resulted in induction of SKP2, in a higher
fraction of cells in S phase and in a significant higher mainte-
nance of the more primitive subsets Lin Kit  (Fig. 8, B–D).
All of these effects were abolished by the presence of the
Notch inhibitor GSI. Taken together, these data show that
abrogation of N1 in adult cells results in mild effects, because
it is compensated readily by other Notch receptors, whereas
an increase in Notch signaling can induce SKP2 and affect cell
cycle and differentiation in vivo. Given that Notch ligands can
be up-regulated in the BM stroma by hormones, such as para-
thyroid hormone (30), and by inflammatory cytokines, such as
TNF-  (unpublished data), we hypothesize that this mecha-
nism could be of physiologic relevance for hematopoietic pro-
genitors’ expansion during BM response to stress conditions.
DISCUSSION
Regulation of the cell cycle, and in particular, of the G1
checkpoint is one of the fundamental mechanisms underly-
ing determination of cell fate (31). Absence of the critical G1
regulators CKIs, p21Cip1 or p27Kip1  or activation of the
Notch receptor, a well-known cell fate regulator (1), induce
similar alterations in the self-renewal/proliferation/differen-
tiation balance of stem and progenitor cells (4, 5, 11, 12).
However, no interaction between these molecular pathways
Figure 7. Stimulation of endogenous Notch by Dll4 ligand pro-
motes SKP2 induction in vivo. (A) N1, Notchic, SKP2, and p27Kip1 expression 
in undifferentiated HL-60 cells. (B) Left panel: HL-60 cells were seeded in 
wells coated with IgG1-Fc control fragment (Fc) or recombinant Dll4-Fc 
fusion protein (Dll4) and cultured in the presence of ATRA. Cell extracts 
obtained from cells at 48 h and 72 h of culture with Fc or Dll4 and ATRA 
were analyzed by Western blot using specific antibodies directed to Val 
1744-cleaved form of Notch (Notchic), SKP2, p27Kip1, and  -actin. Right 
panel: HL-60 cells cultured for 72 h on Fc or Dll4 were incubated with GSI 
( ) or DMSO vehicle control ( ) for an additional 24 h. The white lines 
indicate that intervening lanes have been spliced out. (C) Northern blot 
analysis of SKP2 transcripts in HL-60 cells stimulated with Dll4 or Fc frag-
ment for 72 h. (D) HL-60 cells were induced to differentiate in the presence 
of either ATRA (Co) or ATRA   Dll4 stimulation in the absence or presence 
of GSI. At the indicated days, cells were analyzed for the expression of the 
differentiation marker, CD11b, by FACS. Values indicate an average of 
three independent experiments.JEM VOL. 202, July 4, 2005 165
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has been defined. The present study provides the first dem-
onstration that the F-box protein, SKP2, links Notch signal-
ing with p27Kip1 and p21Cip1 regulation.
Rates of G1-S progression depend on p27Kip1 and p21Cip1
removal from the CDK2 complexes, either by sequestration
by cyclin D-CDK4 complexes or by protein degradation (10).
Previous observations correlated Notch activation with lower
levels of the CDK inhibitor, p27Kip1 (32); however, the direct
link to Notch signaling and the mechanism involved have not
been investigated. Here, we provide evidence that the Notch
signaling pathway regulates the specific degradation of p21Cip1
and p27Kip1 by directly inducing the transcription of SKP2,
the F-box subunit of the ubiquitin-ligase SCFSKP2 that targets
these CKIs for degradation (14). Notch activation recently
was associated with enhanced proteasome-mediated degrada-
tion of E47, a molecule involved in lymphoid cell differentia-
tion (33), suggesting that modulation of protein degradation
could represent a general mechanism through which Notch
signaling modulates cellular processes.
We identified a highly conserved CBF-1 binding motif
within the SKP2 promoter region and demonstrated that
Notch activation drives SKP2 transcription directly through a
CBF-1–dependent mechanism. Notch-mediated SKP2 up-
regulation resulted in a more rapid p21Cip1 and p27Kip1 down-
regulation, increased CDK2 activity, and accelerated cell cy-
cle entry. Furthermore, lack of p21Cip1 resulted in a more
pronounced effect on CDK2 activity and cell cycle progres-
sion in the presence of Notch, perhaps by cooperating with
decreased levels of p27Kip1 in relieving CDK2 inhibition. De-
pletion of SKP2 by siRNA abrogated Notch-induced p27Kip1
down-regulation, and showed that SKP2 is required for
Notch-induced p21Cip1 and p27Kip1 degradation in 3T3 cells.
Elimination of the SKP2/CKI pathway reversed the Notch
effect on cell cycle entry and resulted in a significant reduc-
tion of cells in S phase. However, the effect of Notch on cell
cycle entry was not abolished completely in the absence of
SKP2; this reinforces the present view that Notch signaling
regulates the cell cycle through multiple molecular interac-
tions, as is emerging from several recent reports (34, 35). Al-
though no study has addressed the integrity of the Notch sig-
naling pathway in the SKP2 null cells, SKP2 null mice do not
present the obvious abnormalities of the nervous and lym-
phoid systems derived by altered Notch signaling (20). It is
possible that the specific defect in the Notch/SKP2 pathway
is compensated by alternative pathways or emerges only un-
der conditions of stress. Similarly, loss of N1 did not result in
marked alterations of adult stem and progenitor cells, which
suggests a compensatory effect of other Notch receptors.
The physiologic relevance of our findings is confirmed by
the demonstration that stimulation of endogenous Notch by
its cognate ligand, Dll4, is capable of inducing up-regulation of
SKP2 in the hematopoietic cell line HL-60 and in primary
progenitor cells. In both models, activation of the Notch/
SKP2/CKI pathway correlated with inhibition of progenitor
differentiation and with maintenance of more primitive pre-
cursors, as described previously (24). It is possible that the
Notch/SKP2/CKIs pathway fine tunes the balance of prolifer-
ation and differentiation by accelerating entry into cell cycle
Figure 8. Physiologic relevance of the Notch/SKP2 pathway in 
vivo. (A) SKP2 expression in the absence of N1. RNA obtained from BM 
and spleen cells of N1AS /  and controls were used for RT and PCR ampli-
fication for the indicated gene products. All samples were positive for the 
low molecular size PCR product of the housekeeping gene, GS , which 
confirmed the absence of genomic DNA. Noticeable SKP2 expression was 
found in the spleen cells (left). Bar graph (right) represents densitometric 
values of SKP2 normalized with GS  (densitometric units, DU); values 
indicate averages of three controls and four N1AS    samples (right; 
P   0.064). (B–D) BM Lin  cells sorted from control mice were exposed to 
MS5 cells overexpressing vector alone (Co) or Dll4    GSI. At day 3, cells 
were harvested and processed for the following: (B) PCR for SKP2 and 
GS  and (C) Bromodeoxyuridine incorporation. Bars indicate average per-
centage of cells in S phase in three independent experiments; difference 
between control/GSI and Dll4/GSI is not statistically significant. P   0.1. 
(D) Immunophenotyping: cells were stained with anti–c-Kit antibody and 
analyzed by flow cytometer. Bars indicate average percentage of Lin c-Kit  
cells in three independent experiments. *P   0.03.SKP2 IS A TARGET OF NOTCH SIGNALING | Sarmento et al. 166
and shortening the time spent by cells in G1, the temporal
window where decisions regarding cell cycle withdrawal and
differentiation are made. In support of this view, the CKI
p21Cip1 has been defined as the mediator of the quiescent status
of hematopoietic stem cells, as loss of p21Cip1 results in a tem-
porary stem cell expansion followed by long-term stem cell
exhaustion in vivo (11). Considering that Notch has been
shown to induce p21Cip1 transcription in some cellular systems
(4, 36), and that, in contrast, we observed that it can cause
p21Cip1 down-regulation, we hypothesized that Notch may
regulate hematopoietic stem cell self-renewal through a fine-
tuned balance of these two mechanisms. The Notch/SKP2/
CKI pathway may have a more defined role in the expansion
of hematopoietic progenitors, where p27Kip1 plays a critical
regulatory function. Notch activation (5, 6, 37) and the loss of
p27Kip1 (12) promote hematopoietic progenitor expansion.
Our studies provide evidence that Notch signaling promotes
p27Kip1 degradation and suggest that this may be an important
regulatory mechanism of hematopoietic progenitors expansion
linking microenvironmental cues with the cell cycle effectors.
Neither constitutive loss of p27Kip1 nor constitutive ac-
tivation of Notch results in myeloid cell transformation or
myeloid cell leukemia, suggesting the presence of other neg-
ative regulators in the myeloid lineage. In our experimental
model, Notch activity alone did not bypass the mitogen re-
quirement for SKP2 induction; this suggests that activation
of Notch “per se” is not sufficient to lead to uncontrolled
proliferation. Based on these observations, we propose that
Notch signaling “primes” SKP2 transcriptional activation
during G1 and S phase entry but needs the presence of con-
served cell cycle regulatory mechanisms to accomplish this
function successfully. Thus, by anticipating and reinforcing
SKP2 induction in the presence of mitogens, Notch signal-
ing accelerates entry into the cell cycle (Fig. 9).
The biologic effects that are induced by Notch signaling
are cell context–dependent. In contrast to what is seen in he-
matopoietic stem and progenitor cells, N1 activation se-
verely compromises T cell development and promotes T cell
leukemias (8, 38). In addition, SKP2 was shown to function
as an oncoprotein in some cellular contexts (39) and its over-
expression is common in leukemias and lymphomas (40).
Therefore, it is possible that the capacity of Notch to induce
SKP2 and to down-regulate p27Kip1 expression may consti-
tute the basis of its oncogenic potential in T lymphoid cells.
In conclusion, we propose that the ability of Notch to
modulate a key cell cycle regulator, such as SKP2, plays a
role in balancing proliferation/differentiation in the hemato-
poietic system, and may prove to be critical in cooperating
with additional genetic and epigenetic alterations toward the
acquisition of a malignant phenotype.
MATERIALS AND METHODS
cDNA expression constructs and retroviral transduction. N1 ICN
and  E cDNAs were subcloned into the retroviral vector MSCV-GFP and
used for retroviral infections as described (6). GFP-positive cells were sorted
by fluorescence-activated cell sorting (FACSVantage; Becton Dickinson).
Each individual experiment was performed within 1–2 wk of the transduc-
tion and with pools of GFP-expressing cells to avoid the selection bias. Each
set of experiments was confirmed by multiple independent transductions.
Cell lines and cell culture. Early passage (20–40) 3T3 fibroblasts were
derived from WT and p21 /  mouse embryo as described (16). 293T,
3T3, HL-60, SUP-T1, and MS5 cells were maintained as described (6, 16,
23, 25). Transduced 3T3 cells were treated for 12 h with MG132 (10  M;
Sigma-Aldrich), lactacystin (20  M; AG Scientific, Fluorochem), vehicle
DMSO (1  l/ml; Sigma-Aldrich); or cycloheximide (Sigma-Aldrich, 50
 g/ml final concentration). 3T3 and HL-60 cells were treated with GSI
DFPAA (100 nM; provided by J. Aster, Brigham and Women’s Hospital,
Boston, MA) or vehicle DMSO (1  l/ml; Sigma-Aldrich) for 12 h and 24 h.
HL-60 cells were seeded at 3   105 cells/ml in 6-well plate wells coated
with the Fc portion of human IgG (Fc, Jackson ImmunoResearch Labora-
tories), or with recombinant Dll4 fusion protein consisting of the Dll4 ex-
tracellular domain fused to the Fc portion of human IgG (Dll4-Fc) and
cultured in RPMI 1640 10% FBS supplemented with 2  M ATRA
(Sigma-Aldrich). Dll4-Fc (10  g/ml) or Fc (5  g/ml) was immobilized on
culture wells in 1 ml of PBS (Sigma-Aldrich) overnight at 4 C. MS5-vec-
tor and MS5-Dll4 cell lines were obtained by transducing MS5 cells with
the retroviral vector MSCV-GFP alone or containing the cDNA for Dll4
as described (6).
Mice and primary cultures. C57BL/6 N1AS /  were generated using a
1164-bp N1AS construct encompassing the 5  coding region of mouse N1
expressed under the control of the mouse mammary tumor virus LTR pro-
moter as described (27, 28). Hemizygous transgenic mice N1AS /  were
bread to each other, selecting homozygous transgenic N1AS /  and negative
mice. Transgene integration was confirmed by PCR and transgene expres-
sion and function were confirmed by RT PCR and Western blot analysis for
N1. Age-matched ( 16 wk) adult female mice were used. Primary BM cells
from C57BL/6 control mice were harvested from femurs and labeled with
antibodies directed to lineage markers (Gr1, Mac1, CD3, CD4, CD8, B220,
NK, Ter 199). Lin  (enriched for hematopoietic progenitor cells) were iso-
lated by FACS and seeded on MS5-vector and MS5-Dll4 feeder layers. Lin 
cells were cocultured in IMDM 10% FBS in the absence or presence of 100
nM GSI (Calbiochem); at day 3 of coculture, cells were harvested and pro-
cessed for evaluation of differentiation, cell cycle, and gene expression.
Cell cycle and cell division analysis. 3T3 cells were synchronized in
G2/M, by treatment with 50 ng/ml of nocodazole (Sigma-Aldrich) for 12 h,
and at the G0/G1 boundary by serum starvation (0.1% FCS) for 96 h, fol-
Figure 9. Notch/SKP2/CDK pathway model. (A) In basal conditions, 
mitogen stimulation promotes reentry into the cell cycle by inducing 
SKP2 expression, which in turn, mediates p21Cip1 and p27Kip1 degradation. 
(B) Activation of Notch by its physiologic ligands synergies with mitogen 
stimulation and enforces SKP2 transcription, leading to increased degra-
dation of p21Cip1 and p27Kip1 and to enhanced G1-S transition.JEM VOL. 202, July 4, 2005 167
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lowed by the readdition of serum (10% FCS). The cell cycle was evaluated by
bromodeoxyuridine (Sigma-Aldrich) and propidium iodide (Sigma-Aldrich)
incorporation followed by analysis with the FACSCalibur flow cytometer and
the Cell Quest software (Becton Dickinson). To document cell division his-
tory, 3T3 cells labeled with the red fluorescent membrane dye, PKH26-GL
(Sigma-Aldrich), were seeded at low density in multiple equivalent wells and
each well was harvested every 24 h for 4 d. Collected samples were analyzed
by FACS. Cell division profiles were obtained by evaluating the dilution of
the dye’s mean intensity of fluorescence that occurs at each cell division.
Immunologic reagents and procedures. Immunoprecipitation (IP)
and Western blots were performed as described (16). Gel loading was nor-
malized to protein concentration and confirmed by  -actin probing. Signals
were quantified using Molecular Dynamics scanner and ImageQuant analy-
sis software. Antibodies used included the intracytoplasmic region of N1
(6); cyclin D1 and CDK4 (for IP, provided by E. Harlow); murine p21Cip1
(provided by C. Schneider, Laboratorio Nazionale Biotecnologie, Trieste,
Italy); CBF-1/RBP-J  (provided by E. Kieff, Brigham and Women’s Hos-
pital, Boston, MA; reference 41; Fig. S5, available at http://www.jem.org/
cgi/content/full/jem.20050559/DC1); p27Kip1 (K25020; Transduction
Laboratories); and Notchic (Val 1744; 2421, Cell Signal); and the following:
cyclin A (H-432), cyclin E (M-20), CDK2 (M2), CDK4 (C-22), SKP2
(H-435), and  -actin (I-19), obtained from Santa Cruz Biotechnology, Inc.
Detection of in vivo p27Kip1-ubiquitin conjugates was performed as de-
scribed (21). Lysates (1.5 mg total protein) were IP with anti-p27Kip1 anti-
body (C-19, Santa Cruz Biotechnology, Inc.) and p27Kip1 forms were de-
tected by immunoblotting (K25020; Transduction Laboratories).
Silencing by small interfering RNA. 3T3 cells seeded at a 30–40%
density were serum starved for 96 h before serum (10% FCS) readdition.
The siRNA duplexes that were used for silencing SKP2 or GFP (negative
control) were 21-bp synthetic oligonucleotides synthesized by Dharmacon
Research (SMARTpool). Two rounds of transfections were carried on for
12 h using lipofectamine 2000 reagent (Invitrogen) as recommended.
SKP2 promoter cloning and luciferase assays. The human SKP2 pro-
moter region was identified by analysis of the human genome database and
analyzed for regulatory motifs using the Genome Exploring and Modelling
Software (GEMS) by Genomatix. A region from –3136 to  154, including
the first exon (GenBank sequence accession no. U 33761), was amplified by
PCR using genomic DNA of HL-60 cells and cloned into the pGEM-T
easy vector (Promega). A 3074-bp fragment was subcloned in the SmaI site
of the pGL2-basic vector (Promega) containing the luciferase gene. The
primers used for cloning are: forward 5 -TACAATGAATTAAAGATC-
TACTTAGTTCCAAGC-3  (  3136 to –3103); reverse 5 -ATTCACT-
TAACAGCATTACTAACAATATTAGCC-3  ( 121 to  154).
HES-1luc and  CBF-1-luc luciferase assays were performed using the
HES-1AB and HES-1 AB pGL2 constructs (42). For each experiment,
triplicate wells of 3T3 cells were transfected transiently with pGL2, SKP2-
pGL2,  CBF-1-pGL2, or HES-1-pGL2 together with pSV- -galactosidase
(Promega). Cells were harvested 36–40 h after transfection; luciferase activ-
ity was measured in each sample using a Luciferase Assay kit (Promega) and
TR 717 microplate luminometer (Applied Biosystems). Luciferase readings
were normalized for  -galactosidase activity for each sample.
Northern blot analysis, electrophoretic mobility shift assay, chro-
matin immunoprecipitation, and PCR. RNAs were extracted using
Tri-Reagent (Sigma-Aldrich). Double-strand DNA probes were labeled using
the Prime-it II Random primer labeling kit (Stratagene) and   32P-dATP (Am-
ersham Biosciences). Probes: the 700-bp 5  BamHI fragment from human
SKP2 cDNA (provided by B. Schulman, St. Jude Children’s Research Hospital,
Memphis, TN) and the 429-bp fragment ( 703 to  1131) of mouse  -actin.
For EMSA analysis, 293T cells were transfected transiently with
pcDNA-GFP or CBF-1 and lysed in the 5  extraction buffer. Binding re-
actions were carried on using the  -32P–end-labeled double-stranded oligo-
nucleotide probe containing the CBF-1 binding site. For supershift experi-
ments, 5  l of rabbit polyclonal anti–CBF-1/RBP-J , anti-N1, an unrelated
rabbit antibody (directed to the G-protein SGPR1) or rabbit IgGs, were in-
cubated with the cell extracts before addition of the labeled oligonucleotide.
The oligonucleotides sequences containing the CBF-1 binding motif and
surrounding regions of the SKP2 promoter were: 5 -CGCTACGGCT-
GACTGGGAAATGTCAGCCGCTGGA-3  (WT) and 5 -CGCTACG-
GCTGACCTGGAAATGTCAGCCGCTGGA-3  (mutant).
Chromatin preparation from SUP-T1 cells was cross-linked with en-
dogenous DNA and immunoprecipitated with anti–CBF-1 or anti-N1 anti-
bodies as described (43). Recovered DNA was analyzed by PCR amplifica-
tion. Preliminary experiments with necked DNA were performed to
optimize PCR conditions. The following primers were used to amplified
promoter regions for: SKP2 (200 bp) F: 5 -GATCCACGCTCAGAGAC-
GAC-3 , R: 5 -CCTTCCCTTGCAGCTTTACC-3 ; Hes1 (120 bp) F:
5 -CCAAAGACAGCATCTGAGCAC-3 , R: 5 -GAACGCAGTAC-
CAGCGAGTG-3 ; and CD11b (100 bp) F: 5 -GACCAGGCAGGGC-
TATGT-3 , R: 5 -AAAGCAAAGAAGGGCAGAAA-3 .
RNA from BM, spleen, and sorted Lin  cells was extracted using Tri-
zol (Invitrogen). RNA treated with DNase (Ambion) was used for RT re-
action and PCR. The primers used were: N1: F: 5 -CGGTGTGAGGG-
TGATGTCAATG-3 , R: 5 -GAATGTCCGGGCCAGCGCCACC-3 ;
SKp2: F: 5 -GAGCCAACTCTTCCAAGTGC-3 , R: 5 -AATCCTG-
CACCAATCCTGTC-3 ; Hes1: F: 5 -AACACGACACCGGACAAAC-
3 , R: 5 -GAATGCCGGGAGCTATCTT-3 . The primers for the house-
keeping gene GS  (44), F: 5 -GCTGCTGGCCACCACGAAGAT-3 , R:
5 -GTGATCAAGCAGGCTGACTAT-3 , allow discrimination of con-
taminating genomic DNA by identification of a high molecular product
containing an intervening intron. PCR conditions: 95 5 ; (95 1 ; 64 1 ; 72
1.5 )   32 cycles; 72 10 .
Statistical analysis. Equality of distributions for matched pairs of observa-
tions was tested using the t test.
Online supplemental materials. Fig. S1 shows retroviral transduction.
Fig. S2 shows effects of proteasome inhibition by MG132. Figs. S3 shows
effect of SKP2 inhibition on cell differentiation. Fig. S4 shows hematopoie-
tic subsets in the absence of Notch1. Fig. S5 shows specificity of the anti-
body directed to CBF1/RBP-J . Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20050559/DC1.
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